You are here

HER2 inhbitor

Yuhan makes $325M cancer bet to challenge Boehringer, Takeda

Fierce Pharma

Wed, 05/31/23 - 06:59 pm

Boehringer Ingelheim

non-small cell lung cancer

Buy now, pay later: Jazz hands over $50M for Zymeworks' phase 3 HER2-directed bispecific

Fierce Biotech

Wed, 10/19/22 - 10:42 am

Jazz Pharmaceuticals

bispecific antibodies